Literature DB >> 18365419

Simultaneous antibody-mediated rejection of multiple allografts in modified multivisceral transplantation.

Hidenori Takahashi1, Tomoaki Kato, Kazuo Mizutani, Paul Terasaki, Victor Delacruz, Andreas G Tzakis, Phillip Ruiz.   

Abstract

The patient was an 8-year-old-female with a history of intestinal pseudo-obstruction who underwent a modified multivisceral transplant (stomach, duodenum, pancreas, and small intestine). Following transplantation, she developed HLA antibody (donor-specific and non-donor-specific). Donor-specific HLA antibodies decreased 2 weeks after transplantation, but non-donor-specific HLA antibodies remained high throughout the posttransplant course. The patient experienced repeated acute rejection episodes throughout the post-transplant course, ultimately resulting in the replacement of all allografts 250 days after the initial transplantation. The explanted allografts all revealed acute vascular rejection, but at varying degrees. There was also concurrent chronic rejection, with the intestinal allograft being affected most severely. This case suggests that HLA antibodies played a critical role in antibody-mediated acute rejection and chronic rejection and that there is varying susceptibility to this form of rejection among multiple allografts.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18365419

Source DB:  PubMed          Journal:  Clin Transpl        ISSN: 0890-9016


  2 in total

1.  Serial analysis of biomarkers of acute pancreas allograft rejection.

Authors:  A K Cashion; O Sabek; C Driscoll; L Gaber; E Tolley; A O Gaber
Journal:  Clin Transplant       Date:  2010 Nov-Dec       Impact factor: 2.863

2.  Intercellular adhesion molecular-1, Fas, and Fas ligand as diagnostic biomarkers for acute allograft rejection of pancreaticoduodenal transplantation in pigs.

Authors:  Gao-hong Dong; Xuan-fei Li; Jin-zheng Li; Zhao-da Zhang; Wei-ming Hu; Yu-hong Luo; Zhen-dong Li; Bo-le Tian; Man-xi He; Xi-Wen Zhu
Journal:  Dig Dis Sci       Date:  2013-10-26       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.